Status:
COMPLETED
RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborating Sponsors:
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this research study is to investigate if RAD001 is an effective treatment for pancreatic cancer that has spread and not responded to treatment. Experiments have shown that RAD001 can pr...
Detailed Description
* Participants taking part in this research study will be given a study medication-dosing calendar for each treatment cycle. Each cycle lasts four weeks during which you will be taking the study drug,...
Eligibility Criteria
Inclusion
- Pathologic confirmation of pancreatic adenocarcinoma
- 18 years of age or older
- At least one measurable site of disease according to RECIST criteria that has not been previously irradiated. If patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation.
- Treated with gemcitabine-based chemotherapy with documented tumor progression on gemcitabine or intolerance to gemcitabine.
- Prior treatment with no more than 1 prior chemotherapy regimen for metastatic disease.
- Minimum of two weeks since any major surgery, completion of radiation, or completion of all prior systemic anti-cancer therapy.
- ECOG performance status 0-1.
- Life expectancy of greater than 12 weeks.
- Adequate bone marrow and liver function.
- Must be able to swallow tablets.
Exclusion
- Prior treatment with an investigational drug within the preceding 4 weeks.
- Prior treatment with an inhibitor of mTOR
- Chronic treatment with systemic steroids or another immunosuppressive agent
- More than one prior chemotherapy treatment for metastatic disease
- Uncontrolled brain or leptomeningeal metastases, including patient who continue to require glucocorticoids for brain or leptomeningeal metastases.
- Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin
- Patients with chronic renal insufficiency
- Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study.
- Known history of HIV seropositivity
- Impairment of gastrointestinal function or gastrointestinal disease that my significantly alter the absorption of RAD001.
- Active, bleeding diathesis or an oral vitamin K antagonist medication
- Women who are pregnant or breast feeding
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT00409292
Start Date
January 1 2007
End Date
May 1 2009
Last Update
August 11 2014
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
2
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02115
3
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115